MACROGENICS INC (MGNX) Form 8-K — Jul 7, 2026
MacroGenics completed the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals for $122.5 million. The transaction, which closed on June 30, 2026, includes the transfer of the Rockville, Maryland manufacturing site and Frederick warehouse. Approximately 140 former MacroGenics employees have been hired by Bora as part of the transition. The company received gross proceeds of $122.5 million, subject to customary post-closing adjustments, and entered into a supply agreement to support its internal pipeline needs.
Key figures
- Deal Value Usd
- 122500000
- Net Proceeds Usd
- 110.7 million
- Gain On Derecognition
- 106.1 million
- Employees Transferred
- 140
- Estimated Transaction Costs
- 8.0 million
- Contingent Consideration Usd
- 5 million
Price after filing
Close on the filing date to close N calendar days later (from $4.75). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.